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Abstract
Background: Strategies for use of antiretroviral therapy (ART) have traditionally focused on providing treatment to
persons who stand to benefit immediately from initiating the therapy. There is global consensus that any HIV+ person
with CD4 counts less than 350 cells/μl should initiate ART. However, it remains controversial whether ART is indicated
in asymptomatic HIV-infected persons with CD4 counts above 350 cells/μl, or whether it is more advisable to defer
initiation until the CD4 count has dropped to 350 cells/μl. The question of when the best time is to initiate ART during
early HIV infection has always been vigorously debated. The lack of an evidence base from randomized trials, in
conjunction with varying degrees of therapeutic aggressiveness and optimism tempered by the risks of drug resistance
and side effects, has resulted in divided expert opinion and inconsistencies among treatment guidelines.
Discussion: On the basis of recent data showing that early ART initiation reduces heterosexual HIV transmission, some
countries are considering adopting a strategy of universal treatment of all HIV+ persons irrespective of their CD4 count
and whether ART is of benefit to the individual or not, in order to reduce onward HIV transmission. Since ART has been
found to be associated with both short-term and long-term toxicity, defining the benefit:risk ratio is the critical missing
link in the discussion on earlier use of ART. For early ART initiation to be justified, this ratio must favor benefit over risk.
An unfavorable ratio would argue against using early ART.
Summary: There is currently no evidence from randomized controlled trials to suggest that a strategy of initiating ART
when the CD4 count is above 350 cells/μl (versus deferring initiation to around 350 cells/μl) results in benefit to the
HIV+ person and data from observational studies are inconsistent. Large, clinical endpoint-driven randomized studies
to determine the individual health benefits versus risks of earlier ART initiation are sorely needed.
The counter-argument to this debate topic can be freely accessed here: http://www.biomedcentral.com/1741-7015/11/147.
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Background
Since the first transmissions from chimpanzees to men
almost a century ago [1], HIV continues to spread endem-
ically (and in some regions still epidemically) throughout
the world. Most transmissions occur during sex, whereas
mother-to-child transmission constitutes one-eighth of
the annual 2.5 million new infections [2]. Use of unclean
needles among injecting drug communities also contri-
butes to rapid spread which in Eastern Europe allowed for
a secondary wave of sexual transmission [3].
The prospect of an effective HIV vaccine to contain the
pandemic remains uncertain [4]. Effective interventions to
reduce risk of transmission are diverse and include con-
sistent use of condoms, circumcision of uninfected men
(for acquisition of HIV through heterosexual sex) [5,6],
and use of clean needles for injection of drugs [7]. Al-
though these interventions, when used effectively and
widespread have contained the spread, they are unlikely to
be able to eliminate the HIV pandemic. Hence, other
effective interventions are urgently needed.
In 1994, the first evidence emerged to suggest that low-
ering the replication of HIV in the infected host by use of
antiretroviral therapy (ART) reduced the risk of transmi-
ssion [8]. Pregnant women placed on zidovudine transmit-
ted HIV less frequently to their offspring. This concept
was subsequently simplified (for example, single-dose
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nevirapine and use of a standard ART regimen), and if
used optimally can virtually eliminate mother-to-child
transmission. Although this intervention is available in
most places in the world, 330,000 infants still become
infected each year [2]. This underlines the fact that major
barriers remain within health systems that limit real life
implementation of even this efficacious and relatively
simple intervention.
In 2011, it was conclusively shown that lowering viral
replication in the HIV-infected person also reduces
heterosexual transmission [9]. Major policy changes
have since then been made based on this observation to
dampen global spread of HIV, with the prospect of
having more success than has been accomplished for
mother-to-child transmission.
Left untreated, most infected persons will eventually
die typically from opportunistic complications due to
the resulting immunodeficiency. ART has saved millions
of lives [10,11] after the groundbreaking discovery in
1997 that the duration of effect could be extended by
combining three antiretroviral drugs [12]. However, ART
does not eradicate HIV and, once ART is initiated, it
must be used lifelong without interruption [13]. Invest-
ment in ART treatment programs hence require long-
term commitment from the infected person and the
health system. World Health Organization (WHO)-led
efforts to ensure universal access to ART have resulted
in an accelerated introduction of ART in resource-
limited settings [14]. Nearly half of the funding for this
is provided by donor countries, although the global fund
that manages this process has recently suffered from a
shortage of pledged funds, likely due to the global finan-
cial crisis over the last several years.
Like any medication, ART is associated with adverse
effects. Thus, strategies for use of ART have focused on
providing treatment to persons who stand to benefit
immediately from initiating the therapy. HIV infection
progresses slowly in most persons, and life-threatening
complications in untreated persons usually only start to
emerge several years after the inception of the infection.
The number of circulating CD4+ lymphocytes, the
primary target for HIV, is the best laboratory marker of
HIV-induced immune damage. There is global consen-
sus that any HIV+ person with less than 350 CD4+
lymphocytes per μl blood should initiate ART, as
should HIV+ persons with clinical HIV-related com-
plications of a certain severity regardless of their CD4
count [15-19].
Conversely, it remains controversial whether ART is
indicated in asymptomatic HIV-infected persons with
CD4 counts above 350 cells/μl or whether it is more
advisable to defer initiation until the CD4 count has
dropped to 350 cells/μl or less. The arguments for and
against such ‘early’ (in the course of HIV infection) use
of ART are reviewed below. A divergent expert view has
also been published in BMC Medicine [20].
Discussion
Characteristics of and challenges in diagnosing persons
newly infected with HIV
In regions with concentrated epidemics, average age at
infection is typically around 30 or slightly higher, and
men tend to be more affected than women. Conversely,
in areas with a generalised epidemic, the age at infection
tends to be younger and young women are dispropor-
tionately affected [2].
Most newly infected persons remain undiagnosed. The
testing strategies used in the last two decades remain
ineffective in diagnosing a large percentage of asymp-
tomatic persons early in the course of their infection.
Consequently, 50% or more of HIV+ persons present to
care late in the course of their infection and with CD4
counts below 350 cells/μl [21,22]. Late presentation for
care leads to excess mortality despite initiation of ART
[23,24], higher cost to health systems [25], and is a
missed prevention opportunity [26].
Better and more innovative HIV testing strategies are
urgently needed to address this major public health
challenge [27]. HIV tests were first used in 1985 [28],
but their strategic use to identify persons earlier in the
course of their infection has been remarkably slow. This
is in contrast to the rapid evolution in knowledge on use
of ART and the significant current push to use it early.
In large part, the latter reflects support from the
pharmaceutical industry.
Evidence of benefits from early use of ART
Data from three randomized trials [9,29,30] and from four
observational studies [31-34] support the use of ART
when the CD4 count declines to 350 cells/μl. The entry
CD4 criteria and the deferral strategy of the participants
in the three randomized trials are summarized in Table 1.
A systematic review by the Cochrane Collaboration
was carried out in 2011 [35] before the findings of HIV
Prevention Trials Network study 52 (HPTN 052) were
announced [9,36]. The authors of this review pooled
data from the trial in Haiti [30] and the Strategies
for Management of Anti-Retroviral Therapy (SMART)
subgroup [29]. They reported that the risk of death was
reduced by 74% (relative risk (RR) = 0.26; 95% CI 0.11 to
0.62; P = 0.002). They concluded that ‘there is evidence
of moderate quality that initiating ART at CD4 levels
higher than 200 or 250 cells/μl reduces mortality rates
in asymptomatic ART-naïve, HIV-infected people’ [36].
These data and the data on mortality for HPTN 052 [9]
are summarized in Table 2. The pooled RR for death
with inclusion of HPTN 052 is 0.43 (95% CI 0.24 to
0.77; P = 0.003). The pooled data from the Haiti trial
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and HPTN 052 also indicated that risk of tuberculosis
(TB) is decreased by 49% (95% CI 0.34 to 0.76) with
earlier treatment [9,30]. In the SMART subgroup there
were no cases of TB reported [29]. Therefore, all three
of these trials are providing evidence that ART should be
initiated at CD4 counts higher than 250 cells/μl since
the deferral strategy was consistently to only initiate
ART when the CD4 count dropped to levels below this
threshold. In our opinion, the pooled evidence of trials
with the inclusion of HPTN 052 does not change the
conclusions of the earlier meta-analysis: the evidence
remains moderate that ART should be initiated at CD4
counts higher than 250 cells/μl based on the data from 3
trials in which a total of 53 deaths occurred.
The recommendation to begin ART when the CD4
count declines to 350 cells/μl comes from observational
studies. In this regard, the four observational studies are
consistent. For example in Cain et al. [34], hazard ratios
(HRs) for AIDS or death were 1.37 (95% CI 1.20 to 1.57)
and 1.20 (95% CI 1.05 to 1.38) for CD4 thresholds of
200 and 250 cells/μl versus 350 cells/μl. Corresponding
HRs for death, which were not significant, were 1.18
(95% CI 0.95 to 1.46) and 1.07 (95% CI 0.86 to 1.34).
Using the rating system employed by the group writing
guidelines for the US Department of Health and Human
Services (DHHS) [19] (see below), we believe this rec-
ommendation should be rated BII.
There is no evidence from randomized controlled
trials to suggest that a strategy of initiating ART when
the CD4 count is above 350 cells/μl (versus deferring
initiation to around 350 cells/μl) results in health benefit
to the HIV+ person. The only direct evidence addressing
this question comes from the analyses of the four obser-
vational studies, and the results are inconsistent [31-34]
and all limited by not having data on serious end organ
diseases and cancer. For the question of initiation of
ART between 350 to 500 cells/μl (versus deferring to
CD4 count <350 cells/μl), for example, two of the arti-
cles report an excess risk of death from deferral [31,33],
whereas the two others fail to find evidence of such an
association [32,34]. For the question of initiation above
500 cells/μl (versus deferring to 350 to 500 cells/μl), one
article reported an excess risk of death from deferral
[31], whereas two others failed to find evidence of such
an association [32,33]. Importantly, the observational
studies that these analyses are based on were all
conducted in the last 10 to 12 years, and where the ap-
proach to initiating ART was relatively conservative. As
such, the persons that did indeed start ART early were
not representative of the populations in care at the time,
making the internal and external validities of the find-
ings to the contemporary discussion questionable. The
lack of representativeness is evident from the reported
death rates in the North American AIDS Cohort Collab-
oration on Research and Design (NA-ACCORD) study
[31]. The authors report death rates of 1.6 and 1.3 per
100 person years for those initiating ART between 351
and 500 cells/μl and >500 cells/μl, respectively. These
rates are much higher than reported in the other obser-
vational studies and in large clinical trials [13,37].
Table 1 Summary of baseline characteristics and deferral strategies from randomized controlled trials comparing
deferred vs immediate initiation of antiretroviral therapy (ART) in ART-naïve HIV+ persons
Study (reference) Sample size Median baseline CD4
count (cells/μl)
Deferral strategy Median CD4 count (cells/μl)
at ART initiation in the
deferred arm
SMART [29] 249 437 ART deferred until: 245
1. CD4 declined to <250 cells/μl
2. CD4 percentage declined to <15%
3. Symptoms of HIV disease developed
CIPRA HT-001 [30] 816 281 ART deferred until: 166
1. CD4 declined to ≤200 cells/μl
2. AIDS-defining illness developed
HPTN 052 [9] 1,761 428 ART deferred until: 299
1. CD4 declined to ≤250 cells/μl
2. AIDS-defining illness developed
Table 2 Impact of immediate vs deferred initiation of
antiretroviral therapy (ART) on mortality: data from
randomized controlled trials involving ART-naïve HIV+
persons




SMART [29] 0/131 1/118
CIPRA HT-001 [30] 6/408 23/408
HPTN 052 [9] 10/886 13/877
Pooled data from the
three trials
16/1,425 37/1,403
aEarly ART initiation defined as start of ART at CD4 >350 cells/μl.
bDeferred ART initiation defined as start of ART at CD4 <200 or <250 cells/μl.
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There are numerous studies available to suggest that
untreated HIV (or ongoing viral replication) may be
harmful to the host [13,38-40]. Some experts argue that
our contemporary understanding of the pathogenesis
linking untreated HIV replication to end- organ diseases
and cancer is so evident that earlier ART initiation
would be justified without the need to conduct random-
ized trials [20]. It is beyond the scope of this review art-
icle to critique this body of evidence. Collectively, what
these studies do show is that advanced and untreated
HIV disease is detrimental to health as is intermittent
(or ineffective) use of ART versus continued suppressive
ART, and that those persons who experienced better
CD4 cell recovery will do better than those who do not.
In fact, the standardized mortality ratio for the latter
group (that is, those able to recover to a CD4 count
above 500 cells/μl from typical low nadir CD4 levels
(<200 cells/μl)) approaches one [41,42], suggesting that
prior severe immunodeficiency may not lead to long-
term harm as long as the person recovers a substantive
number of CD4+ lymphocytes and hence experiences
optimal benefit of ART. When ART is initiated in pa-
tients with low nadir CD4 counts, recovery of CD4 cells
may be less likely to occur in a given timespan [43], but
is likely achievable in most patients if viral suppression
is maintained [44]. Recovery of CD4 counts to levels
above 500 cells/μl occurs quickly in virtually all patients
in case ART is initiated around 350 cells/μl [44]. Import-
antly, none of these studies address the question focused
on in this review, namely as compared to deferral of
ART to 350 cells/μl whether initiating ART at a CD4
count higher than 350 cells/μl results in a reduced risk
of morbidity and mortality to the participant with
chronic HIV infection [45]. A clinical trial comparing
early versus later initiation of ART with enough power
to detect differences in incidence of end-organ diseases
and cancer is required to address that question.
Others argue that it takes such a short time to pro-
gress from time of infection to CD4 counts below 500
and 350 cells/μl that it is not worth the bother to delay
initiation of ART as the person will be in need shortly
anyway. However, in the first 2 years following serocon-
version, estimated mean CD4+ count loss has been
shown to range broadly from 88 to 167 cells/μl [46].
Therefore, in a considerable fraction of HIV+ persons, a
long period encompassing several years or even decades
will elapse before the CD4+ count thresholds of 500 and
350 cells/μl are reached.
Why do different expert groups view these data so
differently?
Interpretation of currently available data varies among
experts and treatment guidelines groups. For example, the
Department of Health and Human Services Guidelines
[19] uses the Haiti trial to support their recommendation
of starting at 350 cells/μl and the SMART subgroup and
the HPTN 052 trial to support initiating ART for individ-
uals with a count between 350 and 500 cells/μl. In their
grading scheme ‘A’ is strong evidence, ‘B’ is moderate, ‘C’ is
optional, ‘I’ is data from trials, ‘II’ is data from well-
designed observational studies and ‘III’ is expert opinion.
They rate the evidence as AI for <350 cells/μl; AII for 350
to 500 cells/μl. Their ratings of AI and AII appear to be
based on consideration of the entry criteria for the trials
and not the deferral strategy. WHO [15], again on the
basis of the Haiti and SMART trials, graded the evidence
supporting early ART initiation in another way. Overall,
the recommendation was to defer ART initiation until
CD4 counts decline to <350 cells/μl or an AIDS-defining
illness develops (clinical stage 3 or 4, as per WHO clinical
staging classification of HIV disease). The recommenda-
tion to start ART at CD4 levels between 200 to 250 and
350 cells/μl was considered ‘strong’ by WHO, but the evi-
dence supporting this strategy was considered ‘moderate’.
Earlier use of ART would always show benefit if the
deferral strategy was merely to observe the untreated
HIV infection with no implementation of therapy. The
deferral strategy in all of the quoted randomized con-
trolled trials aimed at starting ART once the CD4 count
dropped below 250 cells/μl, although a substantive
proportion of persons allocated to this arm were allowed
to progress to CD4 count below 200 cells/μl before ART
was initiated. In the most recent of these trials, HPTN
052, the median CD4 count at time of initiation of ART
in the HIV+ persons randomized to deferring ART was
229 cells/μl and with a interquartile range from 197 to
249 cells/μl, implying that 25% of the persons initiated
ART when the CD4 count had dropped below 200 cells/μl
[9]. Hence, our view of these randomized trials, as stated
above, is that they support starting ART above 250 cells/μl.
None of the trials provided evidence for starting ART
between 350 and 500 cells/μl.
The DHHS guidelines use observational data to sup-
port initiating ART >500 cells/μl and their recommenda-
tion is BIII [19]. The rating of ‘III’ seems appropriate,
but as noted above, the findings from the four observa-
tional studies are inconsistent, so in our opinion the full
rating should be CIII, not BIII. The credibility of expert
opinion would be enhanced if the authors of the four
observational studies reconciled their differences and
reported their consensus on the findings. Of note, in the
WHO guidelines, no critical appraisal of the currently
available data supporting (or not) ART initiation in
treatment-naive symptomless HIV+ with CD4 >350
cells/μl was made [15]. No new critical data have been
published since the release of the WHO guidelines in
2010, and hence we must assume that the WHO
remains committed to this appraisal of the evidence.
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Evidence of harm from early use of ART
Recently introduced antiretroviral drugs have fewer side
effects compared to the first and second-generation
drugs developed 10 to 15 years ago. However, central
nervous system toxicity (possibly linked with depression
and suicide) [47-49], renal toxicity (urolithiasis [50] and
progressive worsening of kidney function [51,52]), bone
toxicity (demineralization) [53], and cardiovascular tox-
icity (platelet hyper-reactivity linked with excess coron-
ary artery disease and progressive likely accelerated
atherosclerosis) [54,55] are known adverse reactions to
contemporarily used drugs in resource-rich countries.
It is challenging to conduct research aimed at identify-
ing such adverse drug reactions since many of these
events only develop after extended periods of exposure
and may be infrequent in the relatively healthy popu-
lations allowed to enter short-term trials carried out for
drug registration. Therefore, most of the knowledge on
the clinical adverse drug effect profile from use of ART is
derived from observational studies for which confounding
factors limit the ability to reliably establish causal relation-
ships between drug exposure and specific adverse out-
comes. It is noteworthy that whereas knowledge and
appreciation of benefits from use of an intrinsically effect-
ive antiretroviral drug is fairly easily demonstrated in the
pivotal trials required by authorities for marketing, the
limited sample size and follow-up and the selection of
relatively health participants compromises a comprehen-
sive understanding of possible adverse drug reactions. It
has hence taken several years from when a drug was first
licensed until some of the currently well accepted adverse
drug reactions were identified. For example, it took 7 years
to establish the causal link between use of stavudine or
zidovudine and the development of lipodystrophy [56,57].
As such, it remains uncertain whether the current
knowledge we have on profile of adverse drug reactions
is comprehensive and complete. Recent studies linking
cumulative use of ART with possible excess risk of
cancer serves as a reminder of this [58,59].
The hypothesis that early (versus deferred) use of ART
results in less risk of these various adverse drug reac-
tions has been proposed [60,61] but never conclusively
confirmed in randomized controlled trials. The main
issue that makes this impossible to say is that adverse
drug reactions are often reflected in organ dysfunction,
which untreated HIV (and hence low CD4 count) also
accentuates [62-65]. Hence, whether organ dysfunction
in patients who initiated ART late in the course of HIV
infection is the result of the immunodeficiency or the
antiretroviral drugs used is impossible to differentiate.
Importantly, evaluation of non-fatal adverse drug reac-
tion risk among persons recently infected and initiating
ART is limited since this strategy of using ART has only
recently been introduced and since most cohort studies
are only collecting mortality data, which is a poor proxy
for such reactions.
We believe safety is paramount when interventions are
proposed for target populations at low risk of morbidity
and mortality. As Geoffrey Rose said with respect to an-
other chronic condition: ‘If a preventive measure exposes
many people to a small risk, then the harm it does may
readily (…) outweigh the benefits, since these are received
by relatively few’ [66].
Evidence for defining the benefit:risk ratio for early use of
ART
Whereas initiation of ART at counts <350 cells/μl provides
clear advantages to the HIV+ person, defining the benefit:
risk ratio is the critical missing link in the discussion on
earlier use of ART. For early ART to be justified, this ratio
must favor benefit over risk. An unfavorable ratio would
undermine the argument of using early ART [67,68]. Such
outcomes would violate the basic principle for use of any
type of medicine namely to ‘do no harm’, that is, ‘the doc-
tor should not prescribe medications unless s/he knows
that the treatment is unlikely to be harmful’.
Based on current knowledge, it is not unreasonable to
hypothesize that ART is harmful to use in early HIV
infection. The argument for this is the following. Let us
imagine the optimistic (albeit uncertain) assumption that
early ART provides benefit to the individual. However,
for the person to experience this benefit, the probability
of becoming ill without ART has to be real, otherwise
there is nothing to be gained by being treated. But as the
probability of contracting an AIDS event in early HIV is
low, it is more likely that the person would suffer from
organ dysfunction or cancer; however, the probability of
contracting one of these events is also low in most
recently infected HIV+ persons for several reasons. Most
importantly, most persons get infected relatively early in
life when their risk of these diseases is low. As such,
even though one assumes benefit of early ART on organ
dysfunction and cancer, the probability of contracting
such diseases is low even without ART, and hence many
persons would need to be treated for one to benefit.
Conversely, the risk of adverse drug reactions is real and
will occur irrespective of the person’s age. Newer drugs
used contemporarily lead to less risk of adverse drug
reactions, and as such many need to be treated for one
to be harmed. But if the number needed for one to be
harmed [69] is higher than the number needed to bene-
fit, early ART is of net harm. If this hypothesis is shown
to be correct, this would have major implications not
only for future treatment strategies, but also for those
that have already started ART early, as it is not advisable
to interrupt ART once initiated [13].
Ongoing research aims to clarify the benefit:risk ratio
of early ART. The Strategic Timing of Anti-Retroviral
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Treatment (START) study randomizes asymptomatic
HIV+ persons with CD4 count above 500 cells/μl to
immediate versus deferred (when CD4 count drops to
350 cells/μl) initiation of ART. The study has already
included 4,154 patients and the final sample size of
4,600 is projected to be enrolled by the end of 2013. The
study is endpoint driven: the primary endpoint is AIDS,
organ disease or cancer [70]. The required 213 primary
endpoints are expected to have developed in this cohort
by 2016; an estimate reaffirmed recently by the protocol
leadership when decision on final sample size was made.
Special issues in areas with high tuberculosis (TB)
endemicity
In untreated advanced HIV, the risk of active TB in M.
tuberculosis infected persons is 20-fold higher than in
the background population [71]. Universal initiation of
ART in persons with less than 350 cells/μl will lead to
reduced individual morbidity and mortality and to less
transmission of TB. In support of this, a meta-analysis
published in 2012 found that earlier use of ART reduced
risk of contracting tuberculosis disease [72]. The HPTN
052 study, conducted in high TB endemic regions,
confirmed that deferral of ART to less than 250 cells/μl
(versus starting above 350 cells/μl) leads to excess risk of
tuberculosis, although this benefit was surprisingly seen
for presumptive extrapulmonary TB events only and not
for the more frequently occurring pulmonary TB [9,36].
Conversely, since none of the studies included in the
meta-analysis assessed a deferral strategy of initiating
ART when the CD4 count approached 350 cells/μl
(as such a strategy is not adopted yet in the resource
constrained areas where TB is highly endemic), the
meta-analysis is unable to shed light on whether earlier
use is of benefit to the individual’s health and to reduce
forward transmission of the bacteria within the popula-
tion. In this respect, it is important to be reminded of
one of Muench’s postulates namely that ‘nothing
improves the performance of therapy like the weakness
of controls in its appraisal’ [73].
Treatment as prevention (TasP)
Some countries are considering adopting a strategy of
universal treatment of all HIV+ persons irrespective of
their CD4 count, and irrespective of whether they stand
to receive personal net benefit, to reduce the infectious-
ness of the population and hence dampen transmission
[74-77]. Although the number of ongoing HIV transmis-
sions remains excessive and novel interventions are
attractive to consider, such a strategy is controversial
to implement outside of a research setting for several
reasons. First, as discussed above, it remains uncertain
whether early use of ART is of net benefit to the person
commencing ART. It is controversial to assume that the
benefit of reducing HIV transmission by earlier ART
initiation is equivalent to personal health benefit. Sec-
ond, the public health concerns with using ART as the
primary public health intervention is that this may lead
to a perception in the population that other effective
preventive measures are no longer required. In commu-
nities of men who have sex with men (MSM), such a
‘sexual disinhibition phenomena’ has been observed in
the last decade in studies from Western Europe [78-80]
and in the USA [81]. Third, a public health strategy of
using ART to reduce transmission can only be envisioned
to become effective if the infection is diagnosed very early;
30% to 50% of transmissions occur during the first few
months after the initial infection [80,82] when viral repli-
cation is most extensive [83,84]. Finally, several large
population studies are underway to examine the efficacy
of TasP [85], and it would appear reasonable to await the
results of such trials and the START study before
implementing such a strategy.
Special issues in limited resource settings
The number of new infections is twice as high as the
number of persons initiating ART each year. Hence, a
continued large number of persons in urgent need of
ART (estimated to be 11 million) are not currently
getting this life-saving medication [2]. Most of these
persons live in resource-limited countries. Introducing a
strategy of early use of ART (as part of, for example, a
TasP strategy) hence may distract resources and focus
from the sectors of the population in most urgent need.
Additionally, potential harm from use of early ART in
such settings is higher than is the case in more well-
resourced countries for two principal reasons. First,
older, more toxic drugs (which tend to be cheaper to
produce) are preferentially used [86,87]. Second, the pro-
portion of recent infections being caused by a virus resist-
ant to one or more of the preferred initial components of
ART is increasing in resource-limited settings and the
possibilities for pretreatment resistance testing is very
limited [88]. Initiation of ART composed of drugs where
the virus is resistant to one or more of the drugs provide
suboptimal treatment benefit. Conversely, in settings with
very limited access to determining CD4 counts on a regu-
lar basis, it could be argued that persons approaching the
cut-off of 350 cells/μl (for example, between 350 to 500)
are initiated on ART, as deferral without regular CD4
monitoring is potentially hazardous.
Advice from guidelines
Advice from guidelines may either be based on evidence
or based solely on expert opinion. It is noteworthy that
different guidelines, released at the same time and with
access to the same data, have come out with dissimilar
advice on when in the course of HIV, the individual
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person stands to gain net benefit from initiating ART
[67,68]. Some, like the US DHHS [19] and the Inter-
national Antiviral Society-USA (IAS-USA) guidelines
[16], state that ART is beneficial irrespective of the HIV+
person’s CD4 count, whereas for example the British HIV
Association guidelines do not recommend use in asymp-
tomatic persons with CD4 counts above 350 cells/μl, but
instead call for additional research to address this [17].
Likewise, the European AIDS Clinical Society’s guidelines
stresses that there is clinical equipoise for early or deferred
initiation above 350 cells/μl as evidence is weak [18].
Advice based primarily on expert opinion has played a
major role in HIV medicine over the last two decades, and
several of these recommendations have subsequently not
been supported by solid evidence and hence abandoned.
More generally, it has been pointed out by other authors
that reversals of established practices in many fields are
common [89]. This emphasizes the importance of large
trials to obtain good evidence. For example, many HIV ex-
perts recommended intermittent use of ART; indeed, some
modestly sized studies declared the approach to be ‘safe’,
until the SMART study found in 2006 that such a strategy
was harmful [13]. As such, it would appear reasonable to
view guidance based on expert opinion skeptically.
Strategic use of ART versus ART use by physician
discretion
The critique of early use of ART outlined above focuses
on the strategic use of such a strategy. For the reasons
mentioned above, such a strategic use is problematic as
there is insufficient evidence to support it and may lead
to more harm than benefit to some of those recom-
mended to initiate ART. Conversely, care for individual
persons may (and should be allowed to) lead to initiation
of early ART, provided that the HIV+ person is well
counseled on the lack of evidence, the potential for net
harm, that stopping ART subsequently may lead to even
more harm and that the decision is made in respect for
this person’s rights for personal autonomy and not
unduly influenced by his/her loved ones or the health
professional s/he consults.
The decision to initiate ART in symptomless patients
with early HIV infection is nuanced and each case has to
be evaluated on an individual basis. CD4 cell counts
thresholds are an important, albeit not absolute or
exclusive, parameter upon which such decision should
be based. Indeed, from a biological point of view, it
makes more sense to take into account ranges of CD4
cell counts, as well as the individual speed of decline of
CD4 cell counts, instead of rigid, predetermined thresh-
olds. Finally, even in the hypothetical scenario of a well-
documented favorable risk:benefit ratio for initiating
ART in early HIV infection, sound clinical judgment, in
conjunction with patient willingness and commitment to
initiate a lifelong therapy, will remain a crucial step in
this shared decision-making process.
Use of ART in primary HIV infection
Two important studies were recently published focusing
on use of ART during primary infection [90,91]. These
studies consistently demonstrated that ART can prevent
deterioration of the immune system of the HIV+ person
that otherwise is seen in persons who remain off ART
during and after primary infection. The studies are
encouraging, but relevant for individuals with primary
infection only; this is a group very challenging to identify
in primary care. Conversely, the studies do not address
whether those initiating ART during primary infection
had clinical benefit from doing so (in terms of reduced
morbidity and mortality as the sample in these studies
were <1,000 and hence not powered to address this
question) and conversely whether allowing persons to
progress to lower levels of CD4 count result in any
appreciable negative consequences short or long term.
Only studies appropriately powered to assess clinical
endpoints, requiring substantially larger sample sizes
than were available in these two studies, will be able to
address these outstanding questions.
Summary
When to initiate ART in the course of HIV infection has
been debated ever since the first drug was introduced in
routine care in 1986. ART contemporarily used is effec-
tive and reasonably safe. There is global consensus that
the benefits: risk ratio favors use of ART in any HIV+
person with moderate HIV-induced immunodeficiency or
whom suffers from severe HIV complications, whereas
current evidence makes it uncertain whether this ratio is
also favorable if ART is initiated earlier on the course of
HIV infection. Strategic use of ART in such situations
should be avoided until ongoing research efforts have
been completed.
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